Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29844183 | 1.00 | CYP19A1 (0.32) | CYP19A1CYP11B1CYP11B2ALDH1A1LMNA | |
| SCHEMBL4612462 | 0.98 | CYP19A1 (0.31) | CYP19A1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL7196460 | 0.96 | CYP19A1 (0.30) | CYP19A1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL2970565 | 0.96 | CYP11B1 (0.33) | CYP19A1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL8860745 | 0.96 | CYP11B1 (0.33) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL1453940 | 0.91 | GPR3 (0.33) | LMNA | |
| SCHEMBL7055976 | 0.89 | CYP11B1 (0.33) | CYP19A1CYP11B1CYP11B2ALDH1A1LMNA | |
| SCHEMBL1453690 | 0.88 | — | — | |
| SCHEMBL7053946 | 0.88 | CYP19A1 (0.32) | CYP19A1CYP11B1CYP11B2ALDH1A1LMNA | |
| SCHEMBL1822867 | 0.86 | CYP19A1 (0.31) | CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6232256-B1 | CONTACTING A CYCLOALKADIENYL COMPOUND, A TRANSITION METAL AMIDE, AN ALUMINOXANE, AND OPTIONALLY A SOLID SUPPORT | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION | 2001-05-15 | — | — | US | claimed |
| EP-0933383-A1 | Catalyst composition for the polymerization of olefins | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1999-08-04 | — | — | EP | claimed |
| US-12590174-B2 | Curable compositions comprising telechelic polyolefins | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-03-31 | — | — | US | disclosed |
| EP-3902810-B1 | CURABLE COMPOSITIONS COMPRISING TELECHELIC POLYOLEFINS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-3902808-B1 | CURABLE COMPOSITIONS COMPRISING UNSATURATED POLYOLEFINS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-3356374-B1 | MULTI- OR DUAL-HEADED COMPOSITIONS USEFUL FOR CHAIN SHUTTLING AND PROCESS TO PREPARE THE SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-3902807-B1 | ORGANOMETALLIC CHAIN TRANSFER AGENTS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-12351707-B2 | Curable compositions comprising unsaturated polyolefins | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-12275810-B2 | Telechelic polyolefins and processes for preparing the same | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-04-15 | — | — | US | disclosed |
| US-12180314-B2 | Curable compositions comprising unsaturated polyolefins | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-12129368-B2 | Curable compositions comprising unsaturated polyolefins | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-10-29 | — | — | US | disclosed |
| EP-0692505-A2 | Process for procucing propylene block copolymers | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-01-17 | — | — | EP | disclosed |
| US-5360921-A | REACTING LITHIUM, SODIUM OR POTASSIUM SALT OF A CYCLOPENTADIENE DERIVATIVE WITH A SILICON OR GERMANIUM HALIDE COMPOUND IN THE PRESENCE OF A CYANIDE OR A THIOCYANATE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-01 | — | — | US | disclosed |
| EP-0617044-A2 | Process for preparing cyclopentadienyl group-containing silicon compound or cyclopentadienyl group-containing germanium compound | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1994-09-28 | — | — | EP | disclosed |
| US-5346925-A | Method for producing α-olefin polymers | MITSUBISHI PETROCHEMICAL COMPANY LIMITED (JP) | 1994-09-13 | — | — | US | disclosed |
| EP-0598543-A2 | Method for producing Alpha-olefin polymers | MITSUBISHI CHEMICAL CORPORATION (JP) | 1994-05-25 | — | — | EP | disclosed |
| EP-0566349-A2 | Process for producing alpha-olefin polymers | MITSUBISHI CHEMICAL CORPORATION (JP) | 1993-10-20 | — | — | EP | disclosed |
| US-5225501-A | Transition metal compound and alumoxane catalyst | MITSUBISHI PETROCHEMICAL COMPANY LIMITED (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0529908-A1 | Catalyst useful for the polymerization of olefin | MITSUBISHI CHEMICAL CORPORATION (JP) | 1993-03-03 | — | — | EP | disclosed |
| EP-0512741-A1 | Process for producing a propylene random copolymer | MITSUBISHI CHEMICAL CORPORATION (JP) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129368-B2 | Curable compositions comprising unsaturated polyolefins | ACSL6, ELOVL6, ALOX5 | CYP19A1 2521/4885CYP11B1 3466/4885CYP11B2 3405/4885 |
| US-12590174-B2 | Curable compositions comprising telechelic polyolefins | CCT2, TCP1, ECH1 | CYP19A1 2346/4885CYP11B1 2439/4885CYP11B2 2395/4885 |
| US-12351707-B2 | Curable compositions comprising unsaturated polyolefins | ACSL6, ELOVL6, ALOX5 | CYP19A1 2521/4885CYP11B1 3466/4885CYP11B2 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.